<DOC>
	<DOC>NCT01015521</DOC>
	<brief_summary>This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.</brief_summary>
	<brief_title>Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>ER+ or TN Breast Cancer Progression on an aromatase inhibitor if ER+ Prior treatment with taxane if TN 18 years or older Adequate organ function Measurable lesion symptomatic pulmonary disease brain metastases pregnant females</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>breast cancer</keyword>
</DOC>